Cullinan Therapeutics is advancing CLN-978, a CD19-targeted T-cell engager, for autoimmune diseases with rheumatoid arthritis as the lead indication. The progra

BWB News TV • 2026-08-12 14:26 UTC • By Billy Odell Tucker-Robinson

Cullinan Therapeutics is advancing CLN-978, a CD19-targeted T-cell engager, for autoimmune diseases with rheumatoid arthritis as the lead indication. The program also includes Sjogren’s and lupus, per Q2 2026 pipeline updates.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly